Page 2 - Lupin Pharma
Lupin no longer bullish on Japanese market as price rules prove a dampener
Volumes in that market keep growing at 10 per cent a year, but from a value perspective, the growth is single-digit at best, the firm says
 "Lupin no longer bullish on Japanese market as price rules prove a dampener")
New FDA warning letters show Indian drug makers' quality concerns persist
The latest regulatory crackdown shows US regulator's stance is hardening toward lapses in quality control even as it seeks cheaper drugs to contain health care costs
 "New FDA warning letters show Indian drug makers' quality concerns persist")
Lupin gets US health regulator nod to market hypothyroidism tablets
The product is a generic version of King Pharmaceuticals Research and Development LLC's Levoxyl tablets in same strengths, Lupin said
Glenmark and Lupin: Are pharma stocks a good contrarian bet?
Glenmark Pharma is continuously going down from Rs 600 levels and is not showing any sign of recovery.
 "Glenmark and Lupin: Are pharma stocks a good contrarian bet?")
Lupin's ordeal with USFDA observations continues, shares slump over 10%
Anticipated increase in remediation and compliance costs, and possible delay in drug launches is pushing analysts to cut their forward estimates
 "Lupin's ordeal with USFDA observations continues, shares slump over 10%")
Lupin appoints Sreeji Gopinathan as its Chief Information Officer
Pharma major Lupin Ltd on Thursday said it has appointed Sreeji Gopinathan as its Chief Information Officer (CIO). He will lead the IT function for Lupin globally and will be based in Mumbai. "Sreeji brings to Lupin over 20 years of significant domain expertise and global experience," Lupin said in a statement. Prior to joining Lupin, Gopinathan was with Reckitt Benckiser. He has also been associated with companies including Philips, Procter & Gamble, ISRO and Asea Brown Boveri. "With his substantial experience and ability to closely work with businesses, he will expand and invigorate our initiatives in digitisation, process automation, data management and analytics which will eventually help improve business results," Lupin Managing Director Nilesh Gupta said.
 "Lupin appoints Sreeji Gopinathan as its Chief Information Officer")
Dr Reddy's to Lupin, Indian pharma players get a leg up from domestic sales
Dr Reddy's, Lupin, Sun Pharma and Cadila Healthcare outperformed the local industry growth in recent months, a trend expected to continue
 "Dr Reddy's to Lupin, Indian pharma players get a leg up from domestic sales")
Uncertainty over US biz growth keeps Street cautious on Lupin stock
A strong product pipeline and growth in India and emerging markets are positives, but regulatory hurdles, delayed drug approvals in the US could hurt prospects
Lupin, Boehringer Ingelheim ink $700-mn deal for anti-cancer drug
Lupin will get the marketing rights for the drug in India, while Boehringer Ingelheim will hold the rights to all other markets
Lupin divests its Japanese injectables business to Abu Dhabi company
Company is looking at enhancing efficiencies in Japanese market which is facing pricing pressure
Lupin posts 49% jump in Q1 net profit on the back of strong US sales
The company posted sales of Rs 4,355.8 crore in Q1FY20, which was up marginally from the previous quarter
Lupin gets Establishment Inspection Report from FDA for Aurangabad facility
The facility was inspected by the US Food and Drug Administration
Risk-reward favourable for Lupin as domestic biz provides cushion to growth
Analysts are now upgrading the stock as they expect a recovery for Lupin moving forward, besides a significant improvement in the company's free cash flows
Lupin slips 6% post Q4 results; 3 USFDA observations for Aurangabad unit
The stock dipped 6 per cent to Rs 736 on Thursday, extending its previous day's 3 per cent declined on the BSE.
Lupin to review US lawsuit accusing it of price fixing, customer allocation
The company faces charges along with other companies such as Sun Pharma, Dr Reddy's Laboratories and Wockhardt
Delhi HC sets aside govt ban on Lupin's anti-diabetic drug Gluconorm-30
Government had in 2018 banned Lupin's anti-diabetic drug Gluconorm-30, used to control diabetes
 "Delhi HC sets aside govt ban on Lupin's anti-diabetic drug Gluconorm-30")
Lupin recalls over 24,000 bottles of skin treatment drug from US
The distribution pattern of the product was nationwide in the US and Puerto Rico, says report
 "Lupin recalls over 24,000 bottles of skin treatment drug from US")
Lupin Pharma developing new products to treat cancer, other diseases
The company is focussing on first-to-market kind of opportunities with its new products
 "Lupin Pharma developing new products to treat cancer, other diseases")
Lupin's myotonia treatment drug gets European Commission's approval
The approval makes NaMuscla the first treatment to be licensed throughout the EU for the symptomatic treatment of myotonia in adults with NOM disorders
Lupin receives US FDA approval for antidepressant drug
The product is a generic version of SpecGx LLC's Anafranil capsules in the same strengths
